All New ESRD IV Drugs Should Get Break From Medicare Payment Bundle – Amgen

CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.